ASTRAZENECA PLC
| Revenue | $58.7B |
|---|---|
| Operating income | $13.7B |
| Net income | $10.2B |
| Free cash flow | $11.8B |
| Operating margin | 23.4% |
| Net margin | 17.4% |
| Return on equity | 21.0% |
| Period | 2025 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Operational resilience is encouraging, but legal exposure and governance uncertainty remain unquantified.
Hold: AstraZeneca says China remains operationally normal and delivered 15% growth in the first half, but the call did not resolve the core legal and governance risk.
China is 13% of group revenue; around 100 former employees have reportedly been sentenced over Tagrisso-related insurance fraud, two current and two former senior executives face separate importation/data-privacy investigations, and China profitability is below group average. The absence of a company-directed investigation or guidance change supports the downside case, but Leon Wang’s detention and management’s inability to quantify potential liability make this unsuitable for a fresh buy.
- China Investigations
- Tagrisso
- Medical Insurance Fraud
- Drug Importation
- Data Privacy
- China Pricing
Near term
Next week’s Q3 results and any update to company guidance, China demand, Tagrisso trends, or physician/hospital access are the immediate catalysts.
Watch for additional detentions, charges, company data requests, or indications that authorities are examining AstraZeneca rather than only individuals.
Monitor whether oncology sales or employee engagement show disruption despite management’s business-as-usual characterization.
Longer term
China contributes 13% of revenue but is expected to remain around 13% or decline as Western markets grow faster and offer better pricing and reimbursement.
China’s lower prices after NRDL inclusion, heavy promotional costs, and lower specialty-medicine mix structurally depress margins versus major markets.
The company remains exposed to local competition, although its hospital-channel presence and differentiated oncology portfolio support demand.
AstraZeneca’s ability to launch future medicines in China at attractive economics will depend on reimbursement, approval timing, and the durability of its local innovation and licensing strategy.
Red flags
Leon Wang, EVP International and China President, is detained, while the company says it has no access to the allegations or timeline.
Management could not validate the reported figure of approximately 100 former employees sentenced for medical-insurance fraud because the information came from public sources and families rather than authorities.
Two current and two former senior executives are under investigation for suspected illegal drug importation and patient-data issues; management could not identify the specific conduct or outcomes.
The company repeatedly said it is not under investigation 'as of yet' and declined to estimate potential liability, regulatory repercussions, or the probability of NRDL or procurement consequences.
Management characterized possible Hong Kong-to-mainland medicine flows as limited but could not quantify patient-level volumes; it also described the implicated products as a suspicion, potentially including Enhertu, Imjudo, and Imfinzi.
The call provided no independent evidence that strengthened controls have prevented recurrence; the response relies mainly on newly introduced training, rotations, monitoring, audits, and whistleblowing processes.
Recommendation history
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest ANNUAL · 2026-03-10
- Current Ratio Low
Red flags
- Current Ratio Low — Current ratio 0.94
Upcoming earnings
Earnings transcripts
Press & signals
- Satelight
Dealmaking slowdown threatens early end to M&A boom
- Satelight
Fantasy M&A: the recipe for a European champion
- Satelight
Research Assistant: AstraZeneca's Agentic System for R&D
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans